🚀 VC round data is live in beta, check it out!
TOWA Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for TOWA Pharmaceutical and similar public comparables like Zenas BioPharma, MoonLake, Youcare Pharmaceutical, ArriVent BioPharma and more.
TOWA Pharmaceutical Overview
About TOWA Pharmaceutical
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
Founded
1957
HQ
Employees
3.1K
Website
Sectors
Financials (LTM)
EV
$3B
TOWA Pharmaceutical Financials
TOWA Pharmaceutical reported last 12-month revenue of $2B and EBITDA of $305M.
In the same LTM period, TOWA Pharmaceutical generated $658M in gross profit, $305M in EBITDA, and $129M in net income.
Revenue (LTM)
TOWA Pharmaceutical P&L
In the most recent fiscal year, TOWA Pharmaceutical reported revenue of $2B and EBITDA of $302M.
TOWA Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $658M | XXX | $595M | XXX | XXX | XXX |
| Gross Margin | 37% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $305M | XXX | $302M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $129M | XXX | $130M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | — | — | $1B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TOWA Pharmaceutical Stock Performance
TOWA Pharmaceutical has current market cap of $1B, and enterprise value of $3B.
Market Cap Evolution
TOWA Pharmaceutical's stock price is $27.23.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $1B | -1.8% | XXX | XXX | XXX | $2.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTOWA Pharmaceutical Valuation Multiples
TOWA Pharmaceutical trades at 1.4x EV/Revenue multiple, and 8.4x EV/EBITDA.
EV / Revenue (LTM)
TOWA Pharmaceutical Financial Valuation Multiples
As of April 19, 2026, TOWA Pharmaceutical has market cap of $1B and EV of $3B.
Equity research analysts estimate TOWA Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TOWA Pharmaceutical has a P/E ratio of 10.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 8.4x | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBIT | 15.2x | XXX | 16.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | 4.3x | XXX | XXX | XXX |
| P/E | 10.4x | XXX | 10.3x | XXX | XXX | XXX |
| EV/FCF | 391.1x | XXX | (52.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TOWA Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TOWA Pharmaceutical Margins & Growth Rates
TOWA Pharmaceutical's revenue in the last 12 month grew by 7%.
TOWA Pharmaceutical's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.
TOWA Pharmaceutical's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TOWA Pharmaceutical's rule of X is 35% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
TOWA Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 25% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TOWA Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| TOWA Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Zenas BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| MoonLake | XXX | XXX | XXX | XXX | XXX | XXX |
| Youcare Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| ArriVent BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Inhibrx Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TOWA Pharmaceutical M&A Activity
TOWA Pharmaceutical acquired XXX companies to date.
Last acquisition by TOWA Pharmaceutical was on XXXXXXXX, XXXXX. TOWA Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TOWA Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTOWA Pharmaceutical Investment Activity
TOWA Pharmaceutical invested in XXX companies to date.
TOWA Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. TOWA Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TOWA Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TOWA Pharmaceutical
| When was TOWA Pharmaceutical founded? | TOWA Pharmaceutical was founded in 1957. |
| Where is TOWA Pharmaceutical headquartered? | TOWA Pharmaceutical is headquartered in Japan. |
| How many employees does TOWA Pharmaceutical have? | As of today, TOWA Pharmaceutical has over 3K employees. |
| Is TOWA Pharmaceutical publicly listed? | Yes, TOWA Pharmaceutical is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of TOWA Pharmaceutical? | TOWA Pharmaceutical trades under 4553 ticker. |
| When did TOWA Pharmaceutical go public? | TOWA Pharmaceutical went public in 2004. |
| Who are competitors of TOWA Pharmaceutical? | TOWA Pharmaceutical main competitors are Zenas BioPharma, MoonLake, Youcare Pharmaceutical, ArriVent BioPharma. |
| What is the current market cap of TOWA Pharmaceutical? | TOWA Pharmaceutical's current market cap is $1B. |
| What is the current revenue of TOWA Pharmaceutical? | TOWA Pharmaceutical's last 12 months revenue is $2B. |
| What is the current revenue growth of TOWA Pharmaceutical? | TOWA Pharmaceutical revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of TOWA Pharmaceutical? | Current revenue multiple of TOWA Pharmaceutical is 1.4x. |
| Is TOWA Pharmaceutical profitable? | Yes, TOWA Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of TOWA Pharmaceutical? | TOWA Pharmaceutical's last 12 months EBITDA is $305M. |
| What is TOWA Pharmaceutical's EBITDA margin? | TOWA Pharmaceutical's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of TOWA Pharmaceutical? | Current EBITDA multiple of TOWA Pharmaceutical is 8.4x. |
| What is the current FCF of TOWA Pharmaceutical? | TOWA Pharmaceutical's last 12 months FCF is $7M. |
| What is TOWA Pharmaceutical's FCF margin? | TOWA Pharmaceutical's last 12 months FCF margin is 0%. |
| What is the current EV/FCF multiple of TOWA Pharmaceutical? | Current FCF multiple of TOWA Pharmaceutical is 391.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.